NCT06272149View on ClinicalTrials.gov

An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

January 15, 2025

Study Completion Date

February 28, 2029

Conditions
Type II Gaucher Disease
Interventions
DRUG

VGN-R08b

VGN-R08b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human GBA1 being injected directly into intracerebroventricular.

Trial Locations (1)

200097

RECRUITING

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Vitalgen BioPharma Co., Ltd.

INDUSTRY

lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER